The transcription factor LHX2 mediates and enhances oncogenic BMP signaling in medulloblastoma.

in Cell death and differentiation by Yae Ohata, Mohamad M Ali, Yutaro Tsubakihara, Yuka Itoh, Gabriela Rosén, Tobias Bergström, Anita Morén, Irene Golán-Cancela, Ayana Nakada, Oleksandr Voytyuk, Maiko Tsuchiya, Rei Fukui, Kouhei Yamamoto, Paula Martín-Rubio, Patricia Sancho, Carina Strell, Patrick Micke, Robert J Wechsler-Reya, Yoshinobu Hashizume, Kohei Miyazono, Laia Caja, Carl-Henrik Heldin, Fredrik J Swartling, Aristidis Moustakas

TLDR

  • The study finds that BMP signaling plays a crucial role in medulloblastoma, and that LHX2 is a critical downstream effector of BMP signaling, influencing stemness and chemoresistance.

Abstract

Oncogenic events perturb cerebellar development leading to medulloblastoma, a common childhood brain malignancy. Molecular analyses classify medulloblastoma into the WNT, SHH, Group 3 and Group 4 subgroups. Bone morphogenetic protein (BMP) pathways control cerebellar development and have been linked to the progression of medulloblastoma disease, with major remaining gaps in their mechanistic and clinically-relevant roles. We therefore aimed at exploring BMP mechanisms of action in medulloblastoma. Patient-derived tumors from different subgroups were analyzed in mouse xenografts, complemented by independent tumor immunohistochemical analysis. Cell-based assays analyzed signaling mechanisms. Medulloblastoma cell orthotopic xenografts analyzed tumor growth and metastasis in vivo. Active BMP signaling, detected as nuclear and phosphorylated SMAD1/5, characterized several medulloblastoma subgroups, with enrichment in Group 4, SHH and Group 3 tumors. Spatial transcriptomics in tumor areas, complemented by transcriptomic analysis of multiple cell models, identified BMP-dependent transcriptional induction of the LIM-homeobox gene 2 (LHX2). BMP signaling via SMADs induced LHX2 expression and LHX2 transcriptionally induced BMP type I receptor (ACVR1) expression by association with the proximal promoter region of the ACVR1 gene. BMP signaling and LHX2 gain-of-function expression led to enriched stemness and associated chemoresistance in medulloblastoma cultures. In-mouse orthotopic transplantation of paired primary/recurrent Group 4 medulloblastoma cell populations, correspondingly expressing LHX2-low/BMP-low signaling and LHX2-high/BMP-high signaling, ascribed to the latter (high) group more efficient tumor propagation and spinal cord metastatic potential. Depletion of LHX2 in these recurrent tumor cells suppressed both BMP signaling and tumor propagation in vivo. Thus, LHX2 cooperates with, and enhances, oncogenic BMP signaling in medulloblastoma tumors. The molecular pathway that couples LHX2 function to BMP signaling in medulloblastoma deepens our understanding this malignancy.

Overview

  • The study aimed to investigate the role of Bone Morphogenetic Protein (BMP) signaling in medulloblastoma, a common childhood brain cancer.
  • Patient-derived tumors from different subgroups were analyzed in mouse xenografts, complemented by independent tumor immunohistochemical analysis.
  • The study aimed to identify the mechanisms of action of BMP signaling in medulloblastoma and its potential clinical implications.

Comparative Analysis & Findings

  • Active BMP signaling was detected in several medulloblastoma subgroups, including Group 4, SHH and Group 3 tumors.
  • BMP signaling via SMADs induced the expression of the LIM-homeobox gene 2 (LHX2) and LHX2 transcriptionally induced BMP type I receptor (ACVR1) expression.
  • BMP signaling and LHX2 gain-of-function expression led to enriched stemness and associated chemoresistance in medulloblastoma cultures.

Implications and Future Directions

  • The study highlights the importance of BMP signaling in medulloblastoma and its potential clinical implications for the development of novel therapies.
  • Future studies could build upon this research to explore the potential therapeutic targets of BMP signaling in medulloblastoma.
  • Additionally, investigating the role of LHX2 in medulloblastoma could provide new insights into the biology of this disease and its potential treatment options.